Zolbetuximab: a potential breakthrough in the treatment landscape of gastric cancer

Future Oncol. 2024 Jan;20(2):55-58. doi: 10.2217/fon-2023-0523. Epub 2024 Jan 9.

Authors

Rebecca Ibrahim¹, Khalil Saleh¹, Rita Khoury¹, Nadine Khalife², Claude Chahine¹, Axel Le Cesne¹

Affiliations

¹ International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
² Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

PMID: 38193281
DOI: 10.2217/fon-2023-0523

No abstract available

Keywords: HER2; cldn 18.2; gastric cancer; gastro-esophageal carcinoma; nivolumab; targeted therapy; zolbetuximab.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal
Esophageal Neoplasms*
Esophagogastric Junction
Humans
Nivolumab
Stomach Neoplasms*

Substances

zolbetuximab
Antibodies, Monoclonal
Nivolumab